Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Open access

Abstract

Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of evidence that GLP-1 also acts as an enterogastrone, with profound effects on the gastrointestinal motor system. Moreover, the effects of GLP-1 on gastrointestinal motility appear to be pivotal to its effect of reducing postprandial glycaemic excursions and may, potentially, represent the dominant mechanism. This review summarizes current knowledge of the enterogastrone properties of GLP-1, focusing on its effects on gut motility at physiological and pharmacological concentrations, and the motor actions of incretin-based therapies. While of potential importance, the inhibitory action of GLP-1 on gastric acid secretion is beyond the scope of this paper.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2011/279530

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Blood glucose (a) and plasma insulin (b) concentrations during IV infusion of GLP-1, at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19], and used with permission from the publisher).
Figure 1 Blood glucose (a) and plasma insulin (b) concentrations during IV infusion of GLP-1, at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19], and used with permission from the publisher).CC BY · PubMed Central
Figure 2 Relationship between the area under the plasma glucose concentration curve between 0 and 30 minutes and the retention of the meal in the stomach at 30 minutes (r = 0.65, P < .01) (adapted from Horowitz et al. 1993 [45] and used with the permission of the publisher).
Figure 2 Relationship between the area under the plasma glucose concentration curve between 0 and 30 minutes and the retention of the meal in the stomach at 30 minutes (r = 0.65, P < .01) (adapted from Horowitz et al. 1993 [45] and used with the permission of the publisher).CC BY · PubMed Central
Figure 3 Gastric emptying curves for the solid and liquid components of a meal for the total, proximal, and distal stomach during IV infusion of GLP-1 at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19] and used with permission from the publisher).
Figure 3 Gastric emptying curves for the solid and liquid components of a meal for the total, proximal, and distal stomach during IV infusion of GLP-1 at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19] and used with permission from the publisher).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 111 references

Research works printed but not linked: 16

  1. 1964, The Lancet, 284, 20
  2. 1997, American Journal of Physiology, 273, E981
  3. 2010, Neurogastroenterology & Motility, 22, article e1315, 1191
  4. 10.1210/jc.86.8.3853 · doi:10.1210/jc.86.8.3853 · Paper page
  5. 2004, Diabetes, Nutrition & Metabolism, 17, 336
  6. 1999, American Journal of Physiology, 277, G1217
  7. 1990, American Journal of Physiology, 259, G1031
  8. 1998, American Journal of Physiology, 275, R1293
  9. 1998, American Journal of Physiology, 275, R1308
  10. 1996, Journal of Nuclear Medicine, 37, 1643
  11. 1996, American Journal of Physiology, 271, G814
  12. 2002, American Journal of Physiology, 282, G424
  13. 2000, American Journal of Physiology, 278, G924
  14. 10.1210/jc.87.7.3078 · doi:10.1210/jc.87.7.3078
  15. 2010, Journal of Drug Design, Development and Therapy, 4, 279
  16. 2003, Diabetes, 52, A322

Cited by

See all 138

Metadata

Authors
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M.
Affiliations
Royal Adelaide Hospital (AU)
Corresponding author
Rayner, Christopher K.
Venue
Experimental Diabetes Research
Publisher
Wiley
Published
2011
Volume
2011
Pages
1-10
ISSN
  • 1687-5214 (ISSN-L)
  • 1687-5303
OpenAlex
W2065444806
Cited by
138
References
111
Citations by year
2026: 16 · 2025: 18 · 2024: 20 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 10 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 9 · 2014: 6 · 2013: 12 · 2012: 1
FWCI
4.98
Type
journal article
Language
en
Open access
Locations
  • Experimental Diabetes Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UniSA Research Outputs Repository (University of South Australia) (submittedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
glucagon-like peptide-1, incretin-based therapy, gastrointestinal motility, enterogastrone, type 2 diabetes, anti-obesity, gastric emptying, gastric acid secretion
MeSH terms
Animals, Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Gastrointestinal Motility, Humans, Movement, Peptides, Gastrointestinal Tract, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. https://app.cochat.ai/papers/10.1155/2011/279530
The paper
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011). Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. Experimental Diabetes Research. https://doi.org/10.1155/2011/279530

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.